

# **Identification of novel inhibitor molecules for cancer therapeutics: The c-Myc inhibition story**

A Thesis  
submitted  
by

**Ashutosh Singh**

**(Roll No: D15067)**

for the award of the degree of

**Doctor of Philosophy**




**School of Basic Sciences**

**Indian Institute of Technology Mandi**

**Mandi, Himachal Pradesh-175005**

**September, 2021**

**This page intentionally left blank**

A decorative border surrounds the page, featuring a repeating pattern of small black and white squares. At each of the four corners, there is a large, intricate floral ornament with swirling lines, leaves, and small black dots.

*Affectionately  
dedicated  
to my loving  
parents, wife,  
and  
The Almighty "Shiva"*

**This page intentionally left blank**

### **Declaration by the Research Scholar**

I hereby declare that the entire work embodied in this Thesis entitled “**Identification of novel inhibitor molecules for cancer therapeutics: The c-Myc inhibition story**” is the result of investigations carried out by me in the *School of Basic Sciences*, Indian Institute of Technology Mandi, under the supervision of **Dr. Neha Garg** and that it has not been submitted elsewhere for any degree or diploma. In keeping with the general practice, due acknowledgements have been made wherever the work described is based on finding of other investigators.

IIT Mandi (H.P.)

Date: 14-09-2021



**Ashutosh Singh**

**This page intentionally left blank**



### Declaration by the Research Advisor

I hereby certify that the entire work in this Thesis entitled “**Identification of novel inhibitor molecules for cancer therapeutics: The c-Myc inhibition story**” has been carried out by **Mr. Ashutosh Singh**, under my supervision in the **School of Basic Sciences**, Indian Institute of Technology Mandi, and that no part of it has been submitted elsewhere for any Degree or Diploma. In keeping with the general practice, due acknowledgements have been made wherever the work described is based on finding of other investigators.

BHU, Varanasi

Date: 14-09-2021

**Dr. Neha Garg**

**This page intentionally left blank**



## **Acknowledgments**

I am highly indebted to The Almighty “Shiva” and “Maa Kali,” who gave me the strength to accomplish another chapter of my life. While pursuing my Ph.D. degree, I met many people who encouraged me during ups and downs and provided continuous support of their experience and knowledge throughout this journey. First and foremost, I would like to thank my advisors Dr. Neha Garg for her patience, motivation, constant encouragement, enthusiasm, and immense knowledge. Their guidance helped me in all the research, writing of this thesis, and growing as a researcher.

I also want to express my everlasting gratitude to the stimulating discussions of Doctoral committee members Dr. Venkata Krishnan, Dr. Prem Felix Siril, Dr. Subrata Ghosh, and Dr. Arpan Gupta, who continually conveyed a spirit of adventure regarding my research work. I also want to thankfully acknowledge the Chair, School of Basic Sciences, for providing the laboratory facilities and infrastructure, without which this work would not have been possible to execute. I also express my sincere thanks to our collaborators, Dr. Rajanish Giri, Dr. Venkata Krishnan, Dr. Jaspreet Kaur Randhawa, Dr. Narinder Singh, and Dr. Mohane Selvaraj Coumar, for their constant intellectual involvements, insightful comments, and valuable support. I am also grateful to University Grant Commission (UGC), India, for the financial support during my tenure. I would also like to acknowledge Stem Cell Network, Canada, for supporting my travel to Canada for Till & McCulloch Meetings’ 2018 and 2019. I shall ever remain grateful to all of them.

I express my sincere thanks to the Director, IIT Mandi, for providing high-end facilities in such a remote location. The research facilities at BioX and Advanced Materials Research Center (AMRC), IIT Mandi, are gratefully acknowledged. My sincere

thanks to all BioX faculty members for their invaluable advice and encouragement during course work and research work. I am highly thankful to the BioX and AMRC staff for their assistance in the lab.

My life at IIT Mandi was made pleasurable, entertaining, and memorable in large part due to many friends Mondal, Deepak, Ankur, Nitin, Amit Sir, Bhau, Uddu, Shivani, Prateek, Taniya, Namya, Yogesh, Manish, Suraj, Swati, Dhuni bhai, Ankita, Shounak, Prem, Keshav, Vineeth, Surbhi, Tiwari Ji, Diksha, and Harpreet who encouraged me during my bad times and spent enjoyable moments during my Ph.D. journey.

Lastly, and most importantly, I would like to extend heartfelt gratitude to my parents, my lovely wife, and my younger brother, Ashish, without whom I would never have entered this beautiful journey. I thank my family for their generous support, encouragement, unconditional love, invaluable blessings, and untold sacrifices for my better and bright career. They were always there when I needed them, and without their encouragement and understanding, it would have been impossible for me to take this bumpy ride.

# Table of Contents

<b>Abstract</b> .....	i
<b>Abbreviations</b> .....	iii
<b>Chapter 1:</b>	1
<b>Introduction</b> .....	2
1.1 A brief history of c-Myc.....	2
1.2 Gene and protein domain organization of c-Myc.....	3
1.3 Functional landscape of c-Myc in normal cells .....	6
1.4 c-Myc and cancer.....	7
1.5 Functional landscape of c-Myc in cancer.....	10
1.5.1 c-Myc and cancer initiation.....	11
1.5.2 c-Myc and cancer metabolism.....	12
1.6 c-Myc and therapeutic strategies.....	14
1.6.1 Transcriptional targeting.....	15
1.6.1.1 Bromodomain and extra-terminal (BET) protein inhibitors.....	16
1.6.1.2 G-quadruplex stabilizers.....	16
1.6.2 Post-translational targeting.....	17
1.6.2.1 Protein Phosphatase 2A (PP2A) Activation.....	17
1.6.2.2 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) Inhibition.....	19
1.6.2.3 Enhancing c-Myc degradation.....	20
1.6.2.4 Inhibition of c-Myc/MAX dimerization.....	21
1.7 Challenges and opportunities.....	22
1.8 Thesis outline.....	24
<b>Chapter 2: L755507 identified through computer-aided-drug-discovery efficiently inhibits the c-Myc/MAX heterodimerization and induces apoptosis in cancer cells</b>	
Abstract.....	25
2.1 Introduction.....	26
2.2 Materials and methods.....	27
2.2.1 Cell culture.....	27
2.2.2 Protein structure preparation and druggable site prediction.....	27
2.2.3 Molecular docking.....	28
2.2.4 Molecular dynamics simulations.....	29
2.2.5 Data mining and Myc gene profiling.....	29
2.2.6 Cell viability assay.....	29
2.2.7 Real-time quantitative PCR.....	30
2.2.8 Western blot.....	30

2.2.9 Flow cytometry.....	31
2.2.10 Annexin V/PI apoptosis Assay.....	31
2.2.11 Cell cycle analysis.....	31
2.2.12 Migration assay.....	32
2.2.13 Colony-forming assay.....	32
2.2.14 Co-immunoprecipitation assay.....	32
2.2.15 Isothermal titration calorimetry (ITC).....	33
2.2.16 Fluorescence lifetime measurement.....	33
2.2.17 Time-Resolved anisotropy decay measurement.....	33
2.2.18 Stopped-flow binding kinetics.....	34
2.2.19 Statistical analysis.....	34
2.3 Results.....	35
2.3.1 Identification of potential druggable site and discovery of bioactive molecules that target the bHLH domain.....	35
2.3.2 Myc overexpression is associated with cancer and poor patient survival and is expressed in studied cell lines.....	37
2.3.4 L755507 is a potent molecule that reduces the growth and restricts cell migration and colony-formation of Myc expressing cell lines .....	38
2.3.5 L755507 induces apoptosis and S-phase cell arrest.....	41
2.3.6 L755507 treatment decreases the expression of Myc target genes via abrogating the Myc-MAX dimer.....	43
2.3.7 Biophysical studies demonstrated the binding of L755507 to Myc.....	44
2.3.8 Molecular dynamic (MD) simulations showed a stable interaction of L755507 with Myc.....	47
2.4 Discussion.....	49
<b>Chapter 3: Salvianolic Acid B interacts with the disordered basic helix-loop- helix domain of c-Myc oncoprotein: a computational and spectroscopic based study.</b>	
Abstract.....	57
3.1 Introduction.....	58
3.2 Materials and methods.....	60
3.2.1 Materials.....	60
3.2.2 Myc 3D structure preparation and target site identification.....	60
3.2.3 Molecular docking using Glide.....	61
3.2.4 Binding measurement using fluorescence spectroscopy.....	61
3.2.5 Binding measurement using Circular dichroism (CD) spectroscopy.....	62
3.2.6 Fluorescence lifetime measurement.....	62
3.2.7 Time-Resolved anisotropy decay measurement.....	62
3.2.8 Molecular dynamic simulation.....	63

3.3 Results and discussion.....	63
3.3.1 Identification of druggable site on the disordered bHLH domain of Myc.....	65
3.3.2 Molecular docking study.....	66
3.3.3 Equilibrium binding measurements using fluorescence and CD Spectroscopy.....	66
3.3.4 Change in Myc conformation upon Sal_Ac_B binding as measured through fluorescence lifetime and time-resolved anisotropy.....	67
3.3.5 Extensive MD simulation revealed a stable Myc/Sal_Ac_B complex Formation.....	69
Conclusion.....	71
<b>Chapter 4: Structure-based hot-spot targeting employing conformation ensemble approach led to the discovery of novel c-Myc inhibitors</b>	
Abstract.....	73
4.1 Introduction.....	74
4.2 Materials and methods.....	76
4.2.1 Cell culture.....	76
4.2.2 Disorder prediction.....	76
4.2.3 Hot-spot identification.....	77
4.2.4 Molecular dynamics simulations.....	77
4.2.5 Conformational ensemble generation.....	77
4.2.6 Molecular docking.....	78
4.2.7 In vitro anticancer study.....	78
4.2.8 Real-time quantitative PCR.....	79
4.2.9 Western blot.....	79
4.2.10 Annexin V/Propidium Iodide apoptosis Assay.....	79
4.2.11 Isolation and maintenance of cancer stem cells.....	80
4.2.12 In vitro cytotoxicity on CSC.....	80
4.2.13 Sphere formation assay.....	80
4.2.14 Steady-state fluorescence emission.....	81
4.2.15 Fluorescence lifetime measurements.....	81
4.2.16 Circular dichroism spectral measurements.....	81
4.2.17 Statistical analysis.....	82
4.3 Results.....	81
4.3.1 Identification of hot-spots and warm-spot in c-Myc/MAX interaction.....	81
4.3.2 Structural dynamics of c-Myc through all-atom MD simulations.....	85
4.3.3 Conformation ensemble of c-Myc for docking.....	85
4.3.4 Molecular docking resulted in identification of hit molecules.....	86

4.3.5 Three of the seven compounds showed noteworthy in vitro potency.....	87
4.3.6 The compounds efficiently inhibited the functionality of c-Myc.....	90
4.3.7 The three compounds showed considerable in vitro efficacy against CSCs .....	91
4.3.8 Binding of compounds resulted in the quenching of intrinsic Trp Fluorescence.....	92
4.3.9 Binding of the compounds resulted in time-resolved decrease in Trp fluorescence lifetime.....	93
4.3.10 Compound binding led to decrease in disorderness.....	94
4.3.11 MD simulation showed a stable protein-ligand complex.....	97
4.4 Discussion.....	98
<b>Chapter 5: Conclusion and future perspective</b>	
5.1 Key finding of the thesis.....	105
5.2 Future perspective.....	108
<b>Appendix</b> .....	109
<b>References</b> .....	123
<b>List of publications</b> .....	143